Allergan Urges MDL Judge to Dismiss Biocell Breast Implant Claims as Preempted



DOCUMENTS
  • Brief


TRENTON, N.J. — Allergan USA Inc. is urging the federal judge overseeing the national Biocell breast implant multidistrict litigation to dismiss the claims as preempted, arguing that plaintiffs impermissibly challenge the design, manufacture, labeling and post-sale reporting for the Food and Drug Administration-approved devices.

In a Jan. 5 supplemental brief filed in the U.S. District Court for the District of New Jersey, Allergan says the claims are aimed directly at the FDA’s regulatory oversight and, ultimately, at the requirements governing the manufacture, design, distribution, and reporting for the breast implants and breast tissue extenders.

“As a result, Plaintiffs’ claims trigger …






UPCOMING CONFERENCES




HarrisMartin's Masters of Mass Tort Settlements Conference - Sponsored by Milestone

June 27, 2024 - Buffalo, NY
The Richardson Hotel Buffalo

MORE DETAILS



HarrisMartin's Webinar Series: Video Game Addiction Product Liability Litigation

March 29, 2024

MORE DETAILS